KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Tax Provisions (2016 - 2026)

Biogen has reported Tax Provisions over the past 18 years, most recently at $58.2 million for Q1 2026.

  • For Q1 2026, Tax Provisions fell 17.68% year-over-year to $58.2 million; the TTM value through Mar 2026 reached $251.1 million, down 8.06%, while the annual FY2025 figure was $263.6 million, 3.73% down from the prior year.
  • Tax Provisions for Q1 2026 was $58.2 million at Biogen, up from -$7.1 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $236.2 million in Q3 2022 and troughed at -$72.9 million in Q3 2023.
  • A 5-year average of $80.2 million and a median of $70.7 million in 2025 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: skyrocketed 1011.97% in 2022 and later plummeted 130.86% in 2023.
  • Year by year, Tax Provisions stood at $54.3 million in 2022, then fell by 21.36% to $42.7 million in 2023, then crashed by 41.92% to $24.8 million in 2024, then crashed by 128.63% to -$7.1 million in 2025, then skyrocketed by 919.72% to $58.2 million in 2026.
  • Business Quant data shows Tax Provisions for BIIB at $58.2 million in Q1 2026, -$7.1 million in Q4 2025, and $90.8 million in Q3 2025.